These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 24184931)
21. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P; Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215 [TBL] [Abstract][Full Text] [Related]
22. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270 [TBL] [Abstract][Full Text] [Related]
23. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391 [TBL] [Abstract][Full Text] [Related]
24. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227 [TBL] [Abstract][Full Text] [Related]
26. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Bashshur ZF; Schakal AR; El-Mollayess GM; Arafat S; Jaafar D; Salti HI Retina; 2011 Apr; 31(4):636-44. PubMed ID: 21124254 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
28. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O Retina; 2011; 31(7):1261-7. PubMed ID: 21499194 [TBL] [Abstract][Full Text] [Related]
29. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P; Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Małgorzata F; Stankiewicz A Med Sci Monit; 2011 Sep; 17(9):CR485-90. PubMed ID: 21873944 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS; Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252 [TBL] [Abstract][Full Text] [Related]
32. A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs. Frennesson CI; Nilsson SE Acta Ophthalmol; 2014 May; 92(3):216-20. PubMed ID: 23452436 [TBL] [Abstract][Full Text] [Related]
33. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422 [TBL] [Abstract][Full Text] [Related]
34. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713 [TBL] [Abstract][Full Text] [Related]